Search clinical trials for: DMARDs: Disease-modifying antirheumatic drugs

Total 257149 results

Sabine Dieperink
University of Copenhagen; University of Aarhus; Statens Serum Institut

Completed

Bloodstream Infections in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis | Staphylococcus Aureus Bacteremia
Hoffmann-La Roche

Completed

A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs

Rheumatoid Arthritis

Finland
Hoffmann-La Roche

Completed

An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs

Rheumatoid Arthritis

Slovakia
Hoffmann-La Roche

Completed

A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy (TOSCA)

Rheumatoid Arthritis

France
Merck Sharp & Dohme LLC
AESCA Pharma GmbH

Terminated

Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)

Rheumatoid Arthritis
Hoffmann-La Roche

Completed

ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Italy
Bristol-Myers Squibb

Completed

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

Rheumatoid Arthritis

Belgium, Spain, United States, Germany, Italy, Mexico, United Kingdom, France, Czech Republic, Ireland
Hoffmann-La Roche

Completed

A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent (ACT-MOVE)

Rheumatoid Arthritis

United Kingdom
Noha Mansour

Completed

Montelukast Use in Rheumatoid Arthritis

Rheumatoid Arthritis

Egypt
Hoffmann-La Roche

Completed

A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

United Arab Emirates, Kuwait, Bahrain, Iran, Islamic Republic of, Qatar
Daiichi Sankyo, Inc.

Completed

A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery

Thrombosis | Hip Replacement

Ukraine, United States, Canada, Russian Federation, Hungary, Latvia, Denmark
AbbVie

Completed

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Rheumatoid Arthritis (RA)

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Romania, Russian... and more
Osservatorio Epidemiologico GISEA

Unknown

Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent.

Rheumatoid Arthritis (RA)

Italy
Pfizer

Completed

Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Bristol-Myers Squibb

Completed

Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

Active Polyarticular Juvenile Idiopathic Arthritis

United States, Spain, Belgium, Italy, Argentina, Brazil, France, Germany, Mexico, Peru, Russian Federation, South Africa
AbbVie

Completed

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-BEYOND)

Rheumatoid Arthritis

United States, Australia, Austria, Belgium, Canada, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Korea, Republic of, Latvia, New Zealand, Poland, Portugal, Puerto Rico, Russian Federation, Slovakia, ... and more
Hoffmann-La Roche

Withdrawn

A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs

Rheumatoid Arthritis
Hôpital Cochin

Unknown

Effect of Pharmaceutical Consultations Just Before Rheumatology Consultations on Improving Knowledge and Skills for Patients With Inflammatory Arthritis With Subcutaneous Biologic DMARDs

Arthritis, Rheumatoid | Spondyloarthritis | Biological Therapy

France
Shanghai Henlius Biotech

Completed

A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs

Rheumatoid Arthritis
Hoffmann-La Roche

Completed

An Observational Study to Describe in Routine Clinical Practice the Treatment Patterns of Usage of Biological DMARDs in RA Patients.

Rheumatoid Arthritis

China
Hoffmann-La Roche

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)

Rheumatoid Arthritis

Morocco
University of Tennessee
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Completed

Oral Collagen for Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Hoffmann-La Roche

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF

Rheumatoid Arthritis

Saudi Arabia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Development and Validation of the Prediction Model for Functional Mitral Regurgitation Regression in Heart Failure Patients Taking Guideline-directed Medical Therapy

Heart Failure | Mitral Regurgitation

China
Garlapati Komali

Unknown

Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus

Oral Lichen Planus

India
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (contRAst 3)

Arthritis, Rheumatoid

United States, Germany, Canada, Czechia, Poland, South Africa, Korea, Republic of, Spain, Japan, Argentina, Belgium, Hungary, United Kingdom, Italy, Lithuania
Hoffmann-La Roche

Completed

Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Rheumatoid Arthritis

India
Hoffmann-La Roche
Clalit Health Services

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS

Rheumatoid Arthritis

Israel
Flinders University
medac GmbH; University of South Australia

Recruiting

Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis

Rheumatoid Arthritis | Endothelial Dysfunction | Cardiovascular Risk Factor | Stiffness, Aortic

Australia
Hoffmann-La Roche

Completed

An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.

Rheumatoid Arthritis

Belgium, Czech Republic, France, Italy, Spain, Sweden, United Kingdom, Canada, Greece, Ireland, Portugal, Turkey, Netherlands, Denmark, Finland, Germany, Luxembourg, Austria, Switzerland, Poland, Australia, Hungary, Saudi Arabia, Romania and more
Yonsei University

Not yet recruiting

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) (DOVE)

Uterine Cervical Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Vulvar Cancer | Clear Cell Carcinoma | Vagina Neoplasm
Hoffmann-La Roche

Completed

An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy

Rheumatoid Arthritis

Czech Republic, France, Italy, Spain, United Kingdom, Canada, Portugal, Netherlands, Poland, Australia, Saudi Arabia, Romania, Hungary, Greece
Hoffmann-La Roche

Completed

A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.

Rheumatoid Arthritis

United Kingdom
Helsinki University Central Hospital
Foundation for Paediatric Research, Finland; Päivikki and Sakari Sohlberg Foundation... and other collaborators

Completed

Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (ACUTE-JIA)

Juvenile Idiopathic Arthritis

Finland
Children's Hospital of Fudan University

Recruiting

Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy

Cholangitis | Anti-Bacterial Agents | Biliary Atresia

China
VA Office of Research and Development

Recruiting

Dynamic Treatment Regiments for Glucocorticoid Tapering (SMART-RA)

Rheumatoid Arthritis

United States
University of Sao Paulo General Hospital
GlaxoSmithKline

Recruiting

Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases (RZVRheum)

Rheumatoid Arthritis | Systemic Lupus Erythematosus | Systemic Sclerosis | Juvenile Idiopathic Arthritis | Sjogren's Syndrome | Spondylitis, Ankylosing | Spondyloarthritis | Behçet Disease | Idiopathic Inflammatory Myopathies | Vasculitis, Systemic | Dermatomyositis, Juvenile

Brazil
Novartis Pharmaceuticals

Completed

Risk Perception in Multiple Sclerosis

Multiple Sclerosis

United States
Pfizer

Completed

Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX (ORAL1069)

Arthritis, Rheumatoid

United States, Spain, Taiwan, Bulgaria, Czechia, Hungary, India, Korea, Republic of, Malaysia, Slovakia, Ukraine, Germany, Canada, Argentina, Australia, Thailand, Philippines, Puerto Rico, Brazil, Colombia, Chile, Costa Rica, Mexico, New... and more
Hoffmann-La Roche

Completed

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Rheumatoid Arthritis

France, Germany, Italy, Spain, Sweden, China, United States, Australia, Canada, Mexico, South Africa, United Kingdom, Czech Republic, Finland, Russian Federation, Switzerland, Thailand, Belgium, Denmark, Slovenia, Serbia, Israel, Hong... and more
Janssen Research & Development, LLC

Completed

A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy

Arthritis, Rheumatoid

Poland, Ukraine, Chile, Korea, Republic of, Singapore, Russian Federation, Argentina, Bulgaria, Hungary, Czech Republic
Mashhad University of Medical Sciences
Roche Pharma AG

Completed

Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis

DMARD Resistant Rheumatoid Arthritis

Iran, Islamic Republic of
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Effect of Hemodilution on Intraoperative Allogeneic Transfusion (HEAL)

Bone Tumor | Transfusion | Acute Normovolemic Hemodilution | Goal-Directed Fluid Therapy

China
AbbVie

Not yet recruiting

Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease

Crohn's Disease | Ulcerative Colitis
Assiut University

Not yet recruiting

Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients

Multiple Myeloma
Alexandria University
Tanta University

Recruiting

Impact of Curcumin and Pentoxiphylline on Chronic Kidney Disease Patients (CKD)

Chronic Kidney Disease

Egypt
Ningbo No. 1 Hospital

Recruiting

First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)

Primary Central Nervous System Lymphoma

China
Jilin University

Not yet recruiting

Efficacy of Upadacitinib After NECS in Vitiligo

Vitiligo
Instituto Mexicano del Seguro Social

Recruiting

How to Predict Post-Surgical Bleeding and Hemoglobin in Liposuction?

Bleeding | Surgery

Mexico
CARE ARTHRITIS LTD.

Not yet recruiting

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis (UP-SPOUT)

Psoriatic Arthritis | Spondyloarthritis, Axial

3

Subscribe